Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Thursday, December 11, 2025.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is primarily directed toward medical oncologists, advanced practice providers, oncology nurses, and other health care professionals involved in the diagnosis and management of patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize key characteristics of ESR1 mutations in HR+/HER2- metastatic breast cancer (MBC), including incidence, timing, and impact on treatment efficacy
- Discuss novel therapeutic strategies for targeting the estrogen receptor signaling pathway that have driven the development of next-generation endocrine therapies
- Evaluate safety and efficacy data from recent clinical trials of emerging next-generation endocrine therapies
- Apply new evidence and guideline recommendations to make individualized treatment plans for patients with HR+/HER2- MBC
William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology & Professor of
Medicine
Chief, Division of Hematology/Oncology
Feinberg School of Medicine
Northwestern University
Chicago, IL
Stephanie L. Graff, MD, FACP, FASCO
Associate Professor of Medicine
Warren Alpert Medical School
Brown University
Director of Breast Oncology
Brown Health Cancer Institute
Providence, RI
Cynthia X. Ma, MD, PhD
Professor of Medicine
Clinical Director, Breast Cancer Program
Division of Oncology
Washington University School of Medicine
St. Louis, MO
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.